Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 49, 28, 2, 35 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
•The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
•The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
•The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
•The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
•The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
•The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
•The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
•The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
Reasons to buy•Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
•Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
•Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
•Classify potential new clients or partners in the target demographic.
•Develop tactical initiatives by understanding the focus areas of leading companies.
•Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
•Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
•Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
•Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Introduction
Small-Cell Lung Cancer - Overview
Small-Cell Lung Cancer - Therapeutics Development
Small-Cell Lung Cancer - Therapeutics Assessment
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development
Small-Cell Lung Cancer - Drug Profiles
Small-Cell Lung Cancer - Dormant Projects
Small-Cell Lung Cancer - Discontinued Products
Small-Cell Lung Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2017
Small-Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2017
Small-Cell Lung Cancer - Pipeline by Advantagene Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Small-Cell Lung Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Alchemia Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Amgen Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Aposense Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Aprea AB, H2 2017
Small-Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2017
Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Bayer AG, H2 2017
Small-Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Bionomics Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Small-Cell Lung Cancer - Pipeline by Celgene Corp, H2 2017
Small-Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Checkpoint Therapeutics Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2017
Small-Cell Lung Cancer - Pipeline by Eli Lilly and Co, H2 2017
Small-Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2017
Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2017
Small-Cell Lung Cancer - Pipeline by Immunomedics Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Incyte Corp, H2 2017
Small-Cell Lung Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Ipsen SA, H2 2017
Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2017
Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H2 2017
Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Small-Cell Lung Cancer - Pipeline by MedImmune LLC, H2 2017
Small-Cell Lung Cancer - Pipeline by Merck & Co Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Merck KGaA, H2 2017
Small-Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Moderna Therapeutics Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by MolMed SpA, H2 2017
Small-Cell Lung Cancer - Pipeline by Mologen AG, H2 2017
Small-Cell Lung Cancer - Pipeline by Mundipharma International Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2017
Small-Cell Lung Cancer - Pipeline by NewLink Genetics Corp, H2 2017
Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Novartis AG, H2 2017
Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Pfizer Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Pharma Mar SA, H2 2017
Small-Cell Lung Cancer - Pipeline by Plexxikon Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Rafael Pharmaceuticals Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Recombio SL, H2 2017
Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Sunshine Biopharma Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Tarveda Therapeutics Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Tesaro Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Trovagene Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by United Therapeutics Corp, H2 2017
Small-Cell Lung Cancer - Pipeline by Verastem Inc, H2 2017
Small-Cell Lung Cancer - Pipeline by ViiV Healthcare UK Ltd, H2 2017
Small-Cell Lung Cancer - Pipeline by Xencor Inc, H2 2017
Small-Cell Lung Cancer - Dormant Projects, H2 2017
Small-Cell Lung Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017
Small-Cell Lung Cancer - Dormant Projects, H2 2017 (Contd..2), H2 2017
Small-Cell Lung Cancer - Dormant Projects, H2 2017 (Contd..3), H2 2017
Small-Cell Lung Cancer - Dormant Projects, H2 2017 (Contd..4), H2 2017
Small-Cell Lung Cancer - Dormant Projects, H2 2017 (Contd..5), H2 2017
Small-Cell Lung Cancer - Discontinued Products, H2 2017
Small-Cell Lung Cancer - Discontinued Products, H2 2017 (Contd..1), H2 2017
List of Figures
Number of Products under Development for Small-Cell Lung Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
